3 results
Determining a response characteristic of the vestibulocochlear nerve in healthy subjects (e.g. subjects without hearing loss or tinnitus), for the benefit of assessing possible aberrant characteristics in subjects with tinnitus, which data could be…
Primary:• Phase I part: to define the recommended dose (RD) of nilotinib and vinblastine when used in combination• Phase II part: to evaluate the efficacy of vinblastine in combination with nilotinib (VINILO) at the RD, as compared to vinblastine…
To assess the safety and tolerability profile, in the pre- and perioperative period (up to 30 days post-surgery), of combined modality treatment (CMT) by administering AZD1390 with or without anti PD-L1 checkpoint inhibition and radiotherapy…